TY  - JOUR 
AU  - Gandullo Sánchez, Lucía
AU  - Pandiella Alonso, Atanasio
PY  - 2023
SN  - 0304-3835
SN  - 1872-7980
UR  - http://hdl.handle.net/10366/160885
AB  - [ES] Trastuzumab-emtansine (T-DM1) is an antibody-drug conjugate (ADC) that was approved in 2013 to treat HER2+ breast cancer. Despite its efficacy in the clinic, some patients exhibit intrinsic or acquired resistance to such ADC. To characterize...
LA  - eng
PB  - Elsevier
KW  - HER2
KW  - EGFR
KW  - Breast cancer
KW  - Drug resistance
KW  - Antibody-drug conjugate
KW  - Mamas
KW  - Cáncer
KW  - Microorganismos
KW  - Resistencia a los medicamentos
KW  - Drug Resistance
KW  - Hereditary Breast and Ovarian Cancer Syndrome
TI  - An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugs
DO  - 10.1016/j.canlet.2022.216024
T2  - Cancer Letters
VL  - 554
M2  - 216024
ER  -